CJC-1295 and ipamorelin, explained

Two doors into the same room

The pituitary gland releases growth hormone in response to two separate signals. One is growth-hormone-releasing hormone, which acts on its own receptor and is the body's main accelerator for the system. The other is ghrelin, acting on a different receptor. Ghrelin both amplifies release and suppresses the braking signal that normally holds it down.

CJC-1295 is built to act on the first receptor. Ipamorelin acts on the second. That is the entire pharmacological basis for why they appear together on every clinic menu that carries either of them. It is also the one part of the marketing that is straightforwardly true.

Everything downstream of that is a separate claim requiring separate evidence. The combination is sold as producing a meaningful change in body composition, sleep, recovery, injury healing or how aging feels. None of that follows from the receptor pharmacology, no matter how neatly the diagram works.

The CJC-1295 problem: two molecules, one name

This is the single most important thing here, and almost nothing in the consumer market makes it clear.

CJC-1295 was developed with a chemical modification called a drug affinity complex, usually abbreviated DAC. The DAC lets the peptide bind to albumin in the blood, which protects it from being cleared quickly and gives it a long duration of action. That long-acting version is the one taken into early human trials. Those trials reported sustained increases in growth hormone and IGF-1 after administration. It was not carried through to approval and it is not an approved drug.

What is widely sold under the name CJC-1295 is often labeled 'without DAC' or 'no DAC'. That is not a weaker or plainer version of the same product. Remove the DAC and what remains is modified GRF(1-29), a short-acting growth-hormone-releasing hormone analogue. It has an entirely different duration profile and behaves differently in the body. It is a different molecule wearing the studied molecule's name.

So the human evidence people cite for CJC-1295 is evidence about the long-acting version. A large share of what is actually bought is the short-acting one. Anyone reading a claim about this compound should establish which molecule is being discussed before deciding what the claim is worth. Vendors are not reliably clear about it.

Ipamorelin and the selectivity claim

Ipamorelin is a short synthetic peptide that acts on the ghrelin receptor. The earlier compounds in this family had a well-known drawback. Pushing that receptor also nudged other pituitary hormones, notably cortisol and prolactin, which is not what anyone wanted from a growth hormone secretagogue.

Ipamorelin's original pharmacology described it as releasing growth hormone with markedly less effect on cortisol and prolactin than its predecessors. That selectivity is the compound's actual scientific contribution. It is a real reported finding, not a marketing invention.

It is a finding about which hormones move, though — not about what happens to a person over time. Ipamorelin was carried into clinical development and did not reach approval. It is not an FDA-approved drug. The selectivity data explains why a researcher would find it interesting. It does not establish that taking it produces any outcome a buyer is being promised.

What the pairing has and has not been shown to do

Combining a growth-hormone-releasing hormone analogue with a ghrelin receptor agonist has a coherent rationale. Two different inputs feed the same output, and one of them also lifts the brake. That rationale is why the pairing exists.

It has not been tested as a combination in controlled human trials against the outcomes it is sold for. There is a difference between a combination that makes sense and a combination that has been studied, and the market treats the first as though it settled the second. What follows below describes why the pairing is offered. It gives no guidance on using either compound, alone or together, and contains no dosing, timing or route information.

Be precise about what the underlying evidence measures, even at its best. The strongest human data on either compound concerns hormone concentrations in blood. Growth hormone went up. IGF-1 went up. That is a pharmacodynamic result and it is genuine. It is not a demonstration that fat mass, lean mass, sleep quality, recovery time, joint pain or subjective wellbeing changed. Those are the things people are actually buying.

The comparison that shows what the bar looks like

Tesamorelin is also a growth-hormone-releasing hormone analogue, and it is an FDA-approved drug, approved for a specific indication in a specific population. It got there the ordinary way: by being tested in controlled trials against a defined clinical outcome in the people it was meant to help.

That matters here for two reasons. First, it shows this class of molecule can clear the approval bar. The absence of approved products among CJC-1295 and ipamorelin is not evidence that the bar is unreachable for growth-hormone-releasing hormone analogues generally. Second, it makes the shape of the missing evidence concrete. Nobody needs to speculate about what a convincing trial of CJC-1295 would look like, because a comparable molecule has already had one.

Where the regulatory question sits

Neither CJC-1295 nor ipamorelin is an FDA-approved drug in the United States. Each has its own dated regulatory status record on this site, and that record is where the current position is stated. No summary of it appears here. A summary written into a research article drifts out of date the moment the record changes, and characterizing an outcome, a timeline or a likelihood would go past what is known.

One thing can be said plainly and does not depend on any of that. Material sold in vials labeled for research use only sits outside the prescription drug supply chain. It carries no assurance of identity, purity, sterility or content. That is a different category of thing from a compounded prescription prepared by a licensed pharmacy for an individual patient. Both circulate under these compound names.

How we graded this

Both compounds are graded limited evidence. There is real, measurable, human pharmacology behind each of them: a defined receptor and a documented effect on growth hormone release. That puts them above the compounds whose case rests entirely on cell culture. There is no controlled outcome data supporting the uses they are actually sold for, which keeps them well short of strong.

One qualification belongs with the grade. It is carried by the studied versions of these molecules, and for CJC-1295 the studied version is the long-acting DAC form. A buyer holding a vial labeled 'no DAC' is holding something with less behind it than the grade on this page implies. No amount of shared branding closes that gap.